BAK activation is necessary and sufficient to drive ceramide synthase-dependent ceramide accumulation following inhibition of BCL2-like proteins

Biochemical Journal

Volumn 452, Issue 1, 2013, Pages 111-119

  Beverly, Levi J ^a   Howell, Lauren A ^b   Hernandez Corbacho, Maria ^c   Casson, Lavona ^a   Chipuk, Jerry E ^d   Siskind, Leah J ^b,e  

^a University of Louisville School of Medicine   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

ABT 263; ABT 737; Apoptosis; BCL2; Ceramide; Haematology; Leukaemia; Sphingolipid

Indexed keywords

CERAMIDE; NAVITOCLAX; PROTEIN BAK; PROTEIN BCL 2;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MICROSOME; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANILINE COMPOUNDS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CELL LINE, TUMOR; CERAMIDES; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HUMANS; K562 CELLS; LEUKEMIA; MULTIPLE MYELOMA; OXIDOREDUCTASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; U937 CELLS;

EID: 84876889930     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20130147     Document Type: Article

References (49)

1. Cory, S., Huang, D. C. and Adams, J. M. (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22, 8590-8607
2. Youle, R. J. and Strasser, A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59
3. Lanave, C., Santamaria, M. and Saccone, C. (2004) Comparative genomics: the evolutionary history of the Bcl-2 family. Gene 333, 71-79
4. Sorenson, C. M. (2004) Bcl-2 family members and disease. Biochim. Biophys. Acta 1644, 169-177
5. Beverly, L. J. (2012) Regulation of anti-Apoptotic BCL2-proteins by non-canonical interactions: the next step forward or two steps back? J. Cell. Biochem. 113, 3-12
6. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J. et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681
7. Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M., Ferguson, D., Oleksijew, A., O'Connor, J. M., Wang, B., Frost, D. J. et al. (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 14, 3268-3277
8. Certo, M., Del Gaizo Moore, V., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A. and Letai, A. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351-365
9. Cosulich, S. C., Worrall, V., Hedge, P. J., Green, S. and Clarke, P. R. (1997) Regulation of apoptosis by BH3 domains in a cell-free system. Curr. Biol. 7, 913-920
10. Stewart, M. L., Fire, E., Keating, A. E. and Walensky, L. D. (2010) The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat. Chem. Biol. 6, 595-601
11. Letai, A., Sorcinelli, M. D., Beard, C. and Korsmeyer, S. J. (2004) Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6, 241-249
12. Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S. and Korsmeyer, S. J. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192
13. Reed, J. C. (2006) Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat. Clin. Pract. Oncol. 3, 388-398
14. Kohl, T. M., Hellinger, C., Ahmed, F., Buske, C., Hiddemann, W., Bohlander, S. K. and Spiekermann, K. (2007) BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21, 1763-1772
15. Wesarg, E., Hoffarth, S., Wiewrodt, R., Křoll, M., Biesterfeld, S., Huber, C. and Schuler, M. (2007) Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int. J. Cancer 121, 2387-2394
16. Nguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S. R., Goulet, D., Viallet, J., B́elec, L., Billot, X. et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U.S.A. 104, 19512-19517
17. Del Gaizo Moore, V., Schlis, K. D., Sallan, S. E., Armstrong, S. A. and Letai, A. (2008) BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111, 2300-2309
18. Chen, S., Dai, Y., Harada, H., Dent, P. and Grant, S. (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67, 782-791
19. van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S. et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399
20. Yecies, D., Carlson, N. E., Deng, J. and Letai, A. (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115, 3304- 3313
21. Valdez, B. C., Murray, D., Ramdas, L., de Lima, M., Jones, R., Kornblau, S., Betancourt, D., Li, Y., Champlin, R. E. and Andersson, B. S. (2008) Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk. Res. 32, 1684-1697
22. Yasui, K., Mihara, S., Zhao, C., Okamoto, H., Saito-Ohara, F., Tomida, A., Funato, T., Yokomizo, A., Naito, S., Imoto, I. et al. (2004) Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 64, 1403-1410
23. Colombini, M. (2010) Ceramide channels and their role in mitochondria-mediated apoptosis. Biochim. Biophys. Acta 1797, 1239-1244
24. Siskind, L. J., Kolesnick, R. N. and Colombini, M. (2006) Ceramide forms channels in mitochondrial outer membranes at physiologically relevant concentrations. Mitochondrion 6, 118-125
25. Kim, H. J., Mun, J. Y., Chun, Y. J., Choi, K. H. and Kim, M. Y. (2001) Bax-dependent apoptosis induced by ceramide in HL-60 cells. FEBS Lett. 505, 264-268
26. von Haefen, C., Wieder, T., Gillissen, B., Starck, L., Graupner, V., Dorken, B. and Daniel, P. T. (2002) Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene 21, 4009- 4019
27. Lee, H., Rotolo, J. A., Mesicek, J., Penate-Medina, T., Rimner, A., Liao, W. C., Yin, X., Ragupathi, G., Ehleiter, D., Gulbins, E. et al. (2011) Mitochondrial ceramide-rich macrodomains functionalize Bax upon irradiation. PLoS ONE 6, e19783
28. Chipuk, J. E., McStay, G. P., Bharti, A., Kuwana, T., Clarke, C. J., Siskind, L. J., Obeid, L. M. and Green, D. R. (2012) Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell 148, 988-1000
29. Ganesan, V., Perera, M. N., Colombini, D., Datskovskiy, D., Chadha, K. and Colombini, M. (2010) Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane. Apoptosis 15, 553-562
30. Perera, M. N., Lin, S. H., Peterson, Y. K., Bielawska, A., Szulc, Z. M., Bittman, R. and Colombini, M. (2012) Bax and Bcl-xL exert their regulation on different sites of the ceramide channel. Biochem. J. 445, 81-91
31. Siskind, L. J., Mullen, T. D., Romero Rosales, K., Clarke, C. J., Hernandez-Corbacho, M. J., Edinger, A. L. and Obeid, L. M. (2010) The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis. J. Biol. Chem. 285, 11818-11826
32. Suzuki, M., Youle, R. J. and Tjandra, N. (2000) Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103, 645-654
33. Moldoveanu, T., Liu, Q., Tocilj, A., Watson, M., Shore, G. and Gehring, K. (2006) The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol. Cell 24, 677-688
34. Bielawski, J., Szulc, Z. M., Hannun, Y. A. and Bielawska, A. (2006) Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39, 82-91
35. Ronchini, C. and Capobianco, A. J. (2000) Notch(ic)-ER chimeras display hormone-dependent transformation, nuclear accumulation, phosphorylation and CBF1 activation. Oncogene 19, 3914-3924
36. Casson, L. K., Howell, L., Mathews, L. A., Ferrer, M., Southall, N., Guha, R., Keller, J. M., Thomas, C., Siskind, L. J. and Beverly, L. J. (2013) Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. PLoS ONE 8, e54525
37. Beverly, L. J., Lockwood, W. W., Shah, P. P., Erdjument-Bromage, H. and Varmus, H. (2012) Ubiquitination, localization, and stability of an anti-Apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc. Natl. Acad. Sci. U.S.A. 109, E119-E126
38. Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P. et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 Reference deleted
39. Reference deleted 40 Deng, X., Yin, X., Allan, R., Lu, D. D., Maurer, C. W., Haimovitz-Friedman, A., Fuks, Z., Shaham, S. and Kolesnick, R. (2008) Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans. Science 322, 110-115
40. Merino, D., Khaw, S. L., Glaser, S. P., Anderson, D. J., Belmont, L. D., Wong, C., Yue, P., Robati, M., Phipson, B., Fairlie, W. D. et al. (2012) Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 119, 5807-5816
41. Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A. et al. (2011) Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118, 1663-1674
42. Pewzner-Jung, Y., Ben-Dor, S. and Futerman, A. H. (2006) When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J. Biol. Chem. 281, 25001-25005
43. Kroesen, B. J., Jacobs, S., Pettus, B. J., Sietsma, H., Kok, J. W., Hannun, Y. A. and de Leij, L. F. (2003) BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome. J. Biol. Chem. 278, 14723-14731
44. Senkal, C. E., Ponnusamy, S., Rossi, M. J., Bialewski, J., Sinha, D., Jiang, J. C., Jazwinski, S. M., Hannun, Y. A. and Ogretmen, B. (2007) Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol. Cancer Ther. 6, 712-722
45. Laviad, E. L., Kelly, S., Merrill, Jr., A. H. and Futerman, A. H. (2012) Modulation of ceramide synthase activity via dimerization. J. Biol. Chem. 287, 21025-21033
46. Mullen, T. D., Spassieva, S., Jenkins, R. W., Kitatani, K., Bielawski, J., Hannun, Y. A. and Obeid, L. M. (2011) Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism. J. Lipid Res. 52, 68-77
47. Siskind, L. J., Kolesnick, R. N. and Colombini, M. (2002) Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. J. Biol. Chem. 277, 26796-26803
48. Siskind, L. J., Feinstein, L., Yu, T., Davis, J. S., Jones, D., Choi, J., Zuckerman, J. E., Tan, W., Hill, R. B., Hardwick, J. M. and Colombini, M. (2008) Anti-Apoptotic Bcl-2 family proteins disassemble ceramide channels. J. Biol. Chem. 283, 6622-6630
49. Ganesan, V. and Colombini, M. (2010) Regulation of ceramide channels by Bcl-2 family proteins. FEBS Lett. 584, 2128-2134